X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (18) 18
index medicus (15) 15
chemotherapy (13) 13
humans (13) 13
cetuximab (12) 12
colorectal cancer (12) 12
metastasis (11) 11
aged (10) 10
cancer (10) 10
colorectal neoplasms - drug therapy (10) 10
colorectal neoplasms - pathology (10) 10
middle aged (10) 10
survival (10) 10
bevacizumab (9) 9
female (9) 9
male (9) 9
mutation (9) 9
adult (8) 8
antimitotic agents (8) 8
antineoplastic agents (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
colorectal neoplasms - genetics (8) 8
fluorouracil (8) 8
metastatic colorectal cancer (8) 8
analysis (7) 7
clinical trials (7) 7
colorectal carcinoma (7) 7
leucovorin (7) 7
metastases (7) 7
patients (7) 7
tumors (7) 7
camptothecin - analogs & derivatives (6) 6
irinotecan (6) 6
kras (6) 6
open-label (6) 6
camptothecin - administration & dosage (5) 5
care and treatment (5) 5
neoplasm metastasis (5) 5
therapy (5) 5
antibodies, monoclonal, humanized - administration & dosage (4) 4
disease-free survival (4) 4
fluorouracil - administration & dosage (4) 4
proto-oncogene proteins p21 - genetics (4) 4
treatment outcome (4) 4
1st-line treatment (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
braf (3) 3
cancer research (3) 3
carcinoembryonic antigen (3) 3
cea (3) 3
colorectal neoplasms - mortality (3) 3
drug therapy (3) 3
efficacy (3) 3
epidermal growth factor (3) 3
folfiri plus bevacizumab (3) 3
genes, ras (3) 3
internal medicine (3) 3
kaplan-meier estimate (3) 3
leucovorin - administration & dosage (3) 3
liver metastases (3) 3
liver neoplasms - drug therapy (3) 3
liver neoplasms - secondary (3) 3
medicine & public health (3) 3
organoplatinum compounds - administration & dosage (3) 3
oxaliplatin (3) 3
phase-3 trial (3) 3
phase-iii (3) 3
prognosis (3) 3
proportional hazards models (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
ras mutations (3) 3
ras proteins - genetics (3) 3
retrospective studies (3) 3
solid tumors (3) 3
survival analysis (3) 3
trial (3) 3
adenocarcinoma - drug therapy (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
apoptosis - drug effects (2) 2
bevacizumab - administration & dosage (2) 2
bevacizumab - adverse effects (2) 2
bevacizumab - therapeutic use (2) 2
biomarkers (2) 2
camptothecin - adverse effects (2) 2
capecitabine (2) 2
cell line, tumor (2) 2
cell survival - drug effects (2) 2
cells (2) 2
cetuximab - administration & dosage (2) 2
cetuximab - adverse effects (2) 2
cetuximab - therapeutic use (2) 2
codon (2) 2
codon 12 (2) 2
confidence intervals (2) 2
disease (2) 2
epidermal growth factor receptors (2) 2
evaluation (2) 2
exons (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 07/2012, Volume 23, Issue 7, pp. 1693 - 1699
Journal Article
Der Internist, ISSN 0020-9554, 1/2014, Volume 55, Issue 1, pp. 37 - 42
Zur systemischen Therapie des metastasierten kolorektalen Karzinoms (mKRK) stehen zunehmend mehr Optionen zur Verfügung, die eine sorgfältige Therapieplanung... 
Epidermal-growth-factor-receptor-Antikörper | Nephrology | Epidermal growth factor receptor antibodies | Capecitabine | General Practice / Family Medicine | Internal Medicine | Personalized medicine | Gene, RAS | Irinotecan | Personalisierte Medizin | Medicine & Public Health | Hepatology | Gastroenterology | Capecitabin | Cardiology | Genes, RAS
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 73, pp. 71 - 73
Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2017, Volume 28, Issue suppl_5
Journal Article
Der Internist, ISSN 0020-9554, 01/2014, Volume 55, Issue 1, p. 37
Zur systemischen Therapie des metastasierten kolorektalen Karzinoms (mKRK) stehen zunehmend mehr Optionen zur Verfugung, die eine sorgfaltige Therapieplanung... 
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 79, pp. 50 - 60
Abstract Background RAS and BRAF mutations have been identified as negative prognostic factors in metastatic colorectal cancer. Efficacy of 5-fluorouracil,... 
Hematology, Oncology and Palliative Medicine | BRAF | Cetuximab | RAS | Colorectal cancer | Bevacizumab | PHASE-III | OPEN-LABEL | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | THERAPY | ONCOLOGY | POOLED ANALYSIS | IRINOTECAN | KRAS | SUBGROUP ANALYSIS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - administration & dosage | Liver Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Liver Neoplasms - drug therapy | Exons - genetics | Male | Treatment Outcome | Mutation - genetics | Fluorouracil - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Cetuximab - administration & dosage | Female | Aged | Retrospective Studies | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Viral antibodies | Antimitotic agents | Epidermal growth factor | Gene mutations | Analysis | Antibodies | Genetic aspects | Metastasis | Antineoplastic agents | Epidermal growth factor receptors | 5-Fluorouracil | Colorectal carcinoma | Clinical trials | Shrinkage | Paraffin | Patients | Survival | Subgroups | Metastases | Irinotecan | Mutation | Vascular endothelial growth factor | Tumors | Cancer | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1565 - 1572
Carcinoembryonic antigen (CEA) response may be a surrogate for response and long-term outcome in (K)RAS wild-type mCRC receiving first-line targeted therapy.... 
Tumor marker | FIRE-3 trial | Extended RAS wild-type | KRAS exon 2 wild-type | CEA | Metastatic colorectal cancer | LEUCOVORIN | tumor marker | SOLID TUMORS | MARKERS | extended RAS wild-type | EVALUATION CRITERIA | FLUOROURACIL | CHEMOTHERAPY | THERAPY | ONCOLOGY | SHRINKAGE | metastatic colorectal cancer | CARCINOEMBRYONIC ANTIGEN | MUTATIONS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoembryonic Antigen - genetics | Male | Cetuximab - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Bevacizumab - administration & dosage | Kaplan-Meier Estimate | Exons - genetics | Disease-Free Survival | Cetuximab - administration & dosage | Aged | Mutation | Colorectal Neoplasms - pathology | Index Medicus
Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2017, Volume 84, pp. 262 - 269
We explored the impacts of sequential application of various treatment lines on survival kinetics. Therefore, differences in overall survival (OS) observed in... 
Cetuximab bevacizumab | FIRE-3 | Survival dynamics | Metastatic colorectal cancer | 1ST-LINE TREATMENT | LEUCOVORIN | OPEN-LABEL | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | CETUXIMAB | ONCOLOGY | RAS MUTATIONS | PHASE-3 TRIAL | IRINOTECAN | KRAS | Bevacizumab - therapeutic use | Proto-Oncogene Proteins p21(ras) - genetics | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cetuximab - therapeutic use | Cetuximab - adverse effects | Fluorouracil - therapeutic use | Neoplasm Metastasis | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Leucovorin - therapeutic use | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Camptothecin - therapeutic use | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Biomarkers, Tumor - genetics | Mutation | Colorectal Neoplasms - pathology | Clinical trials | Metastasis | Analysis | Colorectal cancer | Evaluation | Medical treatment | Colorectal carcinoma | Patients | Survival | Bevacizumab | Metastases | Confidence intervals | Survival analysis | Short courses | Randomization | Motivation | Kinetics | Cancer | Index Medicus
Journal Article
International Journal of Cancer, ISSN 0020-7136, 02/2016, Volume 138, Issue 3, pp. 739 - 746
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2013, Volume 24, Issue 12, pp. 3051 - 3055
Journal Article